REG - Ergomed plc - CEL-SCI Corporation issues restricted shares <Origin Href="QuoteRef">ERGO.L</Origin>

ErgomedAnnouncement

21/08/2017 07:10

RNS Number : 5035O
Ergomed plc
21 August 2017
PRESS RELEASE
FOR IMMEDIATE RELEASE
CEL-SCI Corporation issues restricted shares to Ergomed for partial settlement of receivable
London, UK - 21 August 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that it has entered into an agreement with its co-development partner, CEL-SCI Corporation (NYSE: CVM) ('CEL-SCI'), whereby CEL-SCI will issue 480,000 shares of restricted stock which, upon registration, may be sold subject to a volume restriction of no more than five per cent of the trading volume in any single day.
ENDS
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 503205
Dan Weng (Chief Executive Officer)

Stephen Stamp (Chief Financial Officer)



Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)



N+1 Singer
Tel: +44 (0) 20 7496 3000
Alex Price (Joint Broker)



Consilium Strategic Communications - for UK enquiries
Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Philippa Gardner
ergomed@consilium-comms.com


MC Services - for Continental European enquiries
Tel: +49 211 5292 5222
Anne Hennecke



About Ergomed
Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCQFLBLDVFBBBZ